Telitacicept for hard-to-treat IgA kidney disease
Treatments studied
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests telitacicept in people with IgA nephropathy that has not responded well to standard care. It aims to reduce harmful kidney inflammation and protein leakage in the urine.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must sign a consent form and agree to trial procedures.
- Your IgA nephropathy diagnosis must be confirmed by a kidney biopsy.
- You must be age 18 to 70, and your kidney filtering function must be above 35 (GFR/eGFR).
- Your urine test results must show high protein levels for most of the screening visits.
- Before starting, you must already be on a stable dose of an ACE inhibitor or ARB for kidney protection.
- You must not have certain conditions or recent infections, including active tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug (SCTC21C) for people with a type of autoimmune kidney disease called IgA nephropathy. It aims to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This study tests a new medicine called telitacicept for people with IgA nephropathy, a kidney disease that causes protein in the urine. The goal is to see if it safely reduces kidney damage.
This trial tests a new drug called telitacicept to help children whose nephrotic syndrome keeps coming back often or who need steroids to stay in remission. The goal is to see if it can keep urine protein levels low and reduce relapses.
This trial tests if telitacicept can safely help children aged 5–18 with IgA nephropathy or IgA vasculitis nephritis. It aims to reduce protein in the urine and protect kidney function.
This trial tests a targeted medication called Telitacicept for children and teens with kidney inflammation caused by IgA vasculitis. It aims to reduce protein in the urine and protect kidney function.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.